Neurocompute Narrative Velocity Map
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative
Velocity Map

Explore the Parkinson’s research intelligence diagram before entering the Neurocompute platform.

NC
Neurocompute
AI Parkinson’s Intelligence Terminal
NARRATIVE VELOCITY ENGINE

Neurocompute

AI-driven Parkinson’s research intelligence platform exploring emerging signals, forgotten papers, and therapeutic patterns across the biomedical literature universe.

Indexed Papers
1,516
AI Scored
984
Ranked Papers
998
Coverage
1.3%
RESEARCH INTELLIGENCE BOARD

Ranked Parkinson’s Papers

1516 results
LAST INGEST 2026-05-29 06:45 PM
D
AI 15.0
Base 49.2
Rank 46.3
AI Summary

A large RCT in older adults showed the online Rethink My Drink program produced durable reductions in monthly alcohol consumption at 12 months but did not change global cognition.

Why It Matters

This trial is clinically useful for reducing alcohol-related brain health risks in older adults but has limited direct value for Parkinson's therapeutic discovery because it excludes PD patients and provides no mechanistic, biomarker, or targetable insights relevant to PD pathogenesis or drug…

D
Conditional Modeling of GNAO1 Disorder Dissociates Circuit Specific Contributions to Pathology and Rationalizes Ameliorative Strategies.
PMID 41902602 Published: 2026-03-28 Ingested: 2026-04-28 08:58 PM Movement disorders : official journal of the Movement Disorder Society
AI 58.0
Base 47.6
Rank 45.0
AI Summary

Conditional knock-in mice expressing the dominant-negative GNAO1 G203R mutation in specific circuits reveal striatal and forebrain contributions to seizures and motor deficits, region-specific synaptic and proteomic alterations, and that caffeine treatment rescues motor abnormalities.

Why It Matters

Though focused on pediatric GNAO1 encephalopathy, the study provides circuit-specific dissection of G protein signaling, molecular biomarkers, and a repurposed intervention (caffeine), offering experimental strategies and translational leads that could inform Parkinson's motor-circuit targeting and…

D
Dysregulation of astrocytic DNAJC6 contributes to sporadic Parkinson's disease pathogenesis.
PMID 41955024 Published: 2026-04-09 Ingested: 2026-04-28 08:58 PM The Journal of clinical investigation
AI 88.0
Base 47.3
Rank 44.7
AI Summary

The paper shows DNAJC6 is downregulated in neurons and astrocytes in sporadic PD, links that loss to impaired autolysosomal, mitochondrial, phagocytic function and pro-inflammatory astrocyte phenotypes via NURR1/FOXA2 and LRRK2-related mechanisms, and demonstrates that CRISPRa-AAV9–mediated…

Why It Matters

Identifies DNAJC6 as a disease-modifying target that connects key PD pathways (α-synuclein, lysosomes, mitochondria, inflammation, LRRK2) and validates a translational intervention (AAV-CRISPRa) with cell-type specificity, making it highly relevant for therapeutic development and biomarker efforts.

D
Large-scale bidirectional arrayed genetic screens identify OXR1 and EMC4 as modifiers of αSynuclein aggregation.
PMID 41911287 Published: 2026-03-30 Ingested: 2026-04-28 08:58 PM FEBS open bio
AI 80.0
Base 47.3
Rank 44.7
AI Summary

Arrayed CRISPR activation and knockout screens of ~4,700 mitochondria/trafficking genes identified OXR1 activation as promoting Ser129-phosphorylated α-synuclein aggregation via mitochondrial dysfunction and EMC4 ablation as reducing aggregation by enhancing ER-driven autophagic/lysosomal…

Why It Matters

Provides actionable, validated targets—EMC4 for enhancing ER-autophagy to broadly lower α-syn aggregation and OXR1/mitochondrial pathways as modulators of polymorph-specific aggregation—making these high-priority leads for Parkinson’s therapeutic discovery and target development.

D
LINC-EPS Protects Against Neurodegeneration by Driving a PGC-1α-Mediated Anti-Ferroptosis Program in Parkinson's Disease.
PMID 42003904 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM International journal of biological sciences
AI 80.0
Base 47.3
Rank 44.7
AI Summary

This study shows LINC-EPS is reduced in PD patient blood and models, and that LINC-EPS protects dopaminergic neurons by scaffolding PGC-1α to its promoter to boost PGC-1α transcription, improving mitochondrial function and preventing ferroptosis, with AAV-mediated LINC-EPS and the PGC-1α activator…

Why It Matters

Provides a blood-correlated biomarker and a mechanistic, druggable LINC-EPS→PGC-1α anti-ferroptosis axis that supports translational strategies (gene therapy/lncRNA modulation or PGC-1α activation/repurposing) for disease-modifying PD interventions.

D
Synergistic Neurotoxicity of environmental Cadmium and Paraquat in Parkinsonism: Unveiling the Mito-ROS/OPA1/Caspase-3/GSDME-driven Apoptosis Axis.
PMID 41943846 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM International journal of biological sciences
AI 76.0
Base 47.3
Rank 44.7
AI Summary

The study shows that chronic low-dose co-exposure to cadmium and paraquat drives mito-ROS–dependent OPA1 dysregulation, mitochondrial fragmentation, caspase-3–mediated GSDME cleavage, and dopaminergic neuron loss producing PD-like motor and cognitive deficits in mice.

Why It Matters

By linking mitochondrial ROS and OPA1-dependent dynamics to caspase-3/GSDME-driven neuronal apoptosis with in vivo dopaminergic loss, the work identifies actionable targets (mito-ROS, OPA1, caspase-3/GSDME) and an environmental etiologic axis that can inform antioxidant, mitochondrial-dynamics, or…

D
Blood mtDNA markers of mitochondrial subtype and early-onset Parkinson's disease biology.
PMID 41992946 Published: 2026-04-16 Ingested: 2026-04-28 08:58 PM Brain : a journal of neurology
AI 75.0
Base 47.3
Rank 44.7
AI Summary

The paper shows that blood and CSF mtDNA integrity measures (major-arc deletions, 7S DNA abundance, and copy number) are altered in PINK1/PRKN and early-onset idiopathic PD, detectable in prodromal converters, associated with clinical outcomes, and substantially improve group discrimination when…

Why It Matters

These minimally invasive, mechanism-linked mtDNA biomarkers can help stratify patients by mitochondrial involvement and enrich/monitor cohorts for mitochondrial-targeted interventions, increasing translational and trial-readiness value despite limited standalone diagnostic accuracy.

D
Lysosome-Acidifying Nanoparticles Rescue A30P α-Synuclein Induced Neuronal Death in Cellular and Drosophila Models of Parkinson's Disease.
PMID 42033266 Published: 2026-04-25 Ingested: 2026-04-28 08:58 PM Advanced healthcare materials
AI 72.0
Base 47.3
Rank 44.7
AI Summary

The authors developed biodegradable lysosome-acidifying polymeric nanoparticles (AcNPs) that restore lysosomal pH, enhance autophagic clearance of A30P α‑synuclein, improve mitochondrial function, and rescue neuronal loss and motor deficits in cell and Drosophila PD models.

Why It Matters

This provides a mechanistically grounded, actionable proof-of-concept that targeted lysosomal re-acidification can reduce pathogenic α‑synuclein and neurodegeneration, highlighting a novel therapeutic strategy warranting advancement to mammalian models and translational development.

D
Blood-based biomarkers of ferroptosis in Parkinson's disease.
PMID 42035924 Published: 2026-04-24 Ingested: 2026-04-28 08:58 PM Neurobiology of disease
AI 72.0
Base 47.3
Rank 44.7
AI Summary

In a multicenter cohort of 598 PD patients, blood ferroptosis markers—particularly 4-HNE—along with ferritin, selenium and ACSL4 SNPs correlated with baseline disability and one-year motor progression, supporting a link between ferroptosis and disease worsening.

Why It Matters

Provides clinically accessible biomarkers and genetic evidence implicating ferroptosis in PD progression, offering a translational path to stratify patients for trials of ferroptosis-modulating therapies and for targeted repurposing (e.g., iron chelators or ferroptosis inhibitors).

D
Predicting CSF α-Synuclein Seed Amplification Assay Status From Demographics and Clinical Data.
PMID 41982814 Published: 2025-06-01 Ingested: 2026-04-28 08:58 PM Neurology open access
AI 70.0
Base 47.3
Rank 44.7
AI Summary

This study builds and externally validates logistic models using easily obtainable clinical variables (UPSIT smell percentiles, constipation, sex, and LRRK2/GBA status) to accurately predict CSF alpha-synuclein SAA positivity in PD-enriched cohorts (AUROC 0.92–0.98).

Why It Matters

Provides a non-invasive, pragmatic approach to infer alpha-synuclein pathology that can help enrich and triage participants for biomarker-driven trials and reduce reliance on CSF sampling, aiding therapeutic development and patient stratification.

D
CSF alpha-Synuclein Seed Amplification Assay results in routine clinically collected samples.
PMID 41944207 Published: 2026-04-07 Ingested: 2026-04-28 08:58 PM Journal of Parkinson's disease
AI 68.0
Base 47.3
Rank 44.7
AI Summary

This study demonstrates that an alpha-synuclein seed amplification assay applied to routine clinical CSF samples reliably detects Lewy body pathology and aligns well with clinical diagnoses of Parkinson's disease and dementia with Lewy bodies.

Why It Matters

A validated, clinic-ready CSF alpha-synuclein biomarker supports accurate patient stratification and trial enrichment for alpha-synuclein-targeted therapies, improving translational and therapeutic development in Parkinson's disease.

D
Wdfy3-dependent autophagy impairment recapitulates presymptomatic neurodegenerative signatures in mice.
PMID 41935068 Published: 2026-04-04 Ingested: 2026-04-28 08:58 PM Scientific reports
AI 68.0
Base 47.3
Rank 44.7
AI Summary

Wdfy3 haploinsufficiency in mice impairs selective autophagy and produces proteomic and histological signatures that overlap presymptomatic Parkinson's disease, particularly in cortex and substantia nigra.

Why It Matters

This model connects WDFY3/ALFY-dependent autophagy dysfunction to PD-relevant molecular and nigral pathology, offering a translational platform to study early disease mechanisms and to test autophagy-targeted diagnostics or therapies.

D
A Novel 3D Semi-Automated Full Quantification Technique for Detection of Intraneural Phospho-α-Synuclein in Skin Biopsies.
PMID 41995607 Published: 2026-04-01 Ingested: 2026-04-28 08:58 PM European journal of neurology
AI 68.0
Base 47.3
Rank 44.7
AI Summary

This study presents a semi-automated 3D volumetric immunofluorescence quantification method for intraneural S129 phospho-α-synuclein in skin biopsies that discriminates synucleinopathies (PD/MSA) from PSP with high AUC, sensitivity and specificity in a small cohort.

Why It Matters

An objective, burden-sensitive peripheral biomarker for α-synuclein pathology can improve diagnostic accuracy, patient stratification, and target engagement/outcome measures in Parkinson's therapeutic development, though larger neuropathologically confirmed validation is required.

D
AI 65.0
Base 47.3
Rank 44.7
AI Summary

Using Mendelian randomization in large European samples, the study implicates specific plasma lipids (e.g., triacylglycerol and phosphatidylcholine as protective; sphingomyelin as pathogenic), two trace elements (selenium protective; an unexpected iridium signal), and CSF metabolites (including…

Why It Matters

Provides genetically supported, actionable leads linking lipid metabolism and specific CSF metabolites to PD risk and progression—highlighting biomarkers and candidate intervention targets (e.g., phosphatidylcholine, uridine, selenium) that can be prioritized for experimental validation and…

D
AI-Driven Biomarker Discovery in Motor-Related Neurodegenerative Diseases.
PMID 41930586 Published: 2026-03-25 Ingested: 2026-04-28 08:58 PM CNS & neurological disorders drug targets
AI 65.0
Base 47.3
Rank 44.7
AI Summary

This review surveys AI/ML approaches for discovering and validating molecular, imaging, and digital biomarkers related to motor dysfunction across PD, HD, ALS, and SCAs—highlighting candidates such as alpha-synuclein, tau, and neurofilament light chain and the promise of multimodal models while…

Why It Matters

By consolidating actionable biomarker candidates and AI methods, the paper supports improved patient stratification and outcome measures for PD therapeutic development, though translational impact will require stronger cross-center validation and clearer connections from biomarkers to targetable…

D
A refined chronic MPTP/probenecid model of Parkinson's disease in mature adult mice.
PMID 41941954 Published: 2026-04-04 Ingested: 2026-04-28 08:58 PM Experimental neurology
AI 64.0
Base 47.3
Rank 44.7
AI Summary

This study establishes a refined chronic low-dose MPTP/probenecid regimen in mature adult mice that yields progressive motor and cognitive impairments, sustained loss of tyrosine hydroxylase-positive neurons, and phosphorylated α-synuclein aggregation while preserving high survival for longitudinal…

Why It Matters

Delivers a survivable, progressive PD model that better mirrors chronic neurodegeneration and α-synuclein pathology, making it a useful platform for longitudinal therapeutic testing and mechanistic studies (e.g., mitochondrial and synuclein-targeted interventions).

D
Integrated Gait and Pose Analysis Utilizing Computer Vision for Parkinsonian Behavioral Phenotyping in Mice.
PMID 41959468 Published: 2026-03-11 Ingested: 2026-04-28 08:58 PM bioRxiv : the preprint server for biology
AI 64.0
Base 47.3
Rank 44.7
AI Summary

Combines CatWalk gait analysis and DeepLabCut markerless pose estimation in L61 α‑synuclein mice to generate sensitive, complementary motor endpoints (tail‑base lateral variance and hind base of support) that distinguish transgenic from control animals at 12 and 18 months.

Why It Matters

Delivers scalable, objective preclinical motor biomarkers in an α‑synuclein model, improving sensitivity and throughput for therapeutic testing and detection of subtle Parkinson‑like motor progression.

D
Biomarkers of Leucine-Rich Repeat Kinase 2 (LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear Palsy.
PMID 41987507 Published: 2026-04-15 Ingested: 2026-04-28 08:58 PM Movement disorders : official journal of the Movement Disorder Society
AI 62.0
Base 47.3
Rank 44.7
AI Summary

The study reports elevated urine 22:6-BMP in PSP that correlates with CSF total LRRK2, shows that a PD-linked LRRK2 variant associates with higher CSF LRRK2, and that baseline monocyte LRRK2 predicts 1‑year clinical decline, supporting LRRK2 and lysosomal biomarkers in PSP.

Why It Matters

By linking LRRK2 biology and lysosomal dysfunction to clinical progression and genetics in a tauopathy, the work supports repurposing LRRK2-targeted strategies and using fluid biomarkers to stratify patients for neurodegenerative therapy trials.

D
AI 62.0
Base 47.3
Rank 44.7
AI Summary

Combined analysis of skin morphometry (reduced α-syn–positive fibers, increased collagen IV staining and α-syn–positive melanocytes) plus salivary α-syn oligomers discriminates Parkinson's patients from controls and correlates with clinical scores.

Why It Matters

Offers minimally invasive, α-syn–related biomarkers that can improve diagnostic accuracy and patient stratification and serve as complementary endpoints for PD therapeutic development and trials.

D
Circ-find-0001774 Modulates Parkinson's Disease via miR-153-3p: Mechanistic Insights and Therapeutic Implications.
PMID 41910841 Published: 2026-03-30 Ingested: 2026-04-28 08:58 PM Journal of molecular neuroscience : MN
AI 60.0
Base 47.3
Rank 44.7
AI Summary

The paper shows that circ-find-0001774 sponges miR-153-3p to boost Wnt/β-catenin signaling, lowering autophagy/apoptosis and improving dopaminergic neuron survival and motor behavior in MPP+/MPTP PD models.

Why It Matters

Provides a mechanistically actionable circRNA–miRNA–Wnt/β‑catenin axis with in vivo neuroprotective effects that could inform novel therapeutic strategies, although human relevance and delivery/translation hurdles remain.

D
AI 58.0
Base 47.3
Rank 44.7
AI Summary

Using explainable radiomic features from standard T1/T2 MRI in basal ganglia and ventral midbrain, the study accurately discriminates PD, SWEDD, and healthy controls (macro-AUC 0.85) and highlights ventral midbrain texture heterogeneity and thalamic contrast as top predictors.

Why It Matters

Provides a low-burden, explainable MRI biomarker for patient stratification and trial enrichment that can guide targeted quantitative imaging and hypothesis generation in Parkinson's research, though it offers limited direct mechanistic or therapeutic targets.

D
AI 58.0
Base 47.3
Rank 44.7
AI Summary

Using resting-state fNIRS and graph-theory, the study found that Parkinson's patients with wearing-off exhibit a less efficient cortical network (reduced clustering and global efficiency, increased path length) with nodal abnormalities in premotor and somatosensory cortices, and that global…

Why It Matters

Suggests a non-invasive, bedside-accessible candidate biomarker (reduced global efficiency) for objective detection and individualized monitoring of wearing-off, which could improve clinical management and outcome measures in PD trials.

D
AI 58.0
Base 47.3
Rank 44.7
AI Summary

Autoradiographic [18F]nifene binding to α4β2* nicotinic acetylcholine receptors is markedly increased in the hippocampus–subiculum of postmortem Parkinson's disease brains compared with controls, with noted sex- and age-related differences.

Why It Matters

This identifies upregulated α4β2* nAChRs as a promising PET biomarker for PD diagnosis and stratification and points to a receptor system that could be explored for therapeutic modulation, though functional/mechanistic validation is required for drug discovery use.

D
Decomposed Transfer Entropy for EEG Brain Networks: Parkinson's Disease and Dopaminergic Modulation.
PMID 41941809 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society
AI 58.0
Base 47.3
Rank 44.7
AI Summary

Introduces Decomposed Transfer Entropy (DTE) to separate phase, spectral amplitude, and interaction contributions to directed EEG connectivity and shows PD patients off medication exhibit a phase-dominant reweighting from frontal midline (Fz) that shifts toward healthy patterns with dopaminergic…

Why It Matters

Provides a mechanism-aware, noninvasive EEG biomarker that discriminates PD from controls and tracks medication-related normalization of network communication—useful for stratifying patients and monitoring therapeutic effects, though it does not directly identify new molecular drug targets.

D
Neurovascular dysfunction in the development and progression of neuroinflammatory diseases.
PMID 41909487 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Frontiers in cellular neuroscience
AI 58.0
Base 45.5
Rank 44.7
AI Summary

This review synthesizes evidence that neurovascular unit (NVU) and blood–brain barrier (BBB) dysfunction driven by immune mechanisms and disease-specific insults (e.g., α-synuclein in PD) contributes to neuroinflammation and neuronal injury across neurodegenerative diseases.

Why It Matters

By linking NVU/BBB disruption and immune-mediated vascular pathology to α-synuclein and other disease processes, the paper highlights vascular and neuroimmune mechanisms as potential therapeutic targets and biomarker opportunities for Parkinson's disease, though it is primarily a conceptual review…

Previous
Page 15 of 61
Next
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic
Full Neurocompute Infographic